Bank of America Merrill Lynch (NYSE:BAC) cut German pharma giant Merck KGA’s stock today, from neutral to underperform, on earnings risk from its Erbitux and Rebif drugs and communication problems with investors.
The company is not related to the US-based drug company Merck (NYSE:MRK).
Merck KGA is a component of German ETFs, such as the iShares MSCI Germany Index Fund (AMEX:EWG). The fund has just 0.71% of Merck KGA in its portfolio, with Siemens (SI) as its top stock, at 10.31% of holdings, and BASF, Bayer, Daimler and E.ON rounding out the top five.
This Article's Word Cloud:AMEXAmericaBASFBankBayerDaimlerETFsErbituxFundGermanGermanyIndexLynchMSCIMerckMerrillNYSERebifSiemensbasedcommunicationcompanycomponentdrugdrugsearningsfivefromfundgiantholdingsiSharesinvestorsjustneutralpharmaportfolioproblemsrelatedriskroundingstocksuchtodayunderperformwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.